NY state has granted clinical permit to the first liquid biopsy-based ExoDx Prostate test
This is exciting news for all of the exosome researchers out there. Exosomes have been studied for about three decades now and multiple clinical applications have been proposed. One specific application was using exosomes for liquid biopsy for diagnostic purposes.
This test assists physicians in determining the need for a prostate biopsy in patients with an ambiguous prostate specific antigen (PSA) test result. It tests for three exosomal RNA biomarkers to enable physicians to assess whether a patient presenting for an initial biopsy is at greater risk for high-grade prostate cancer.